Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …

Recurrent venous thromboembolism (VTE) is associated with increased morbidity and
mortality. This risk is lowered by anticoagulation, with a large effect in the initial phase …

The need for extended venous thromboembolism (VTE) treatment beyond 3 to 6 months is
usually determined by balancing the risk of recurrence if treatment is stopped against the …

A diagnosis of recurrent venous thromboembolism is commonly suspected by physicians in
the clinical setting. Many do not realize that recurrent venous thromboembolism may mimic …

Background Observational studies suggest index clinical manifestation of venous
thromboembolism (VTE) predicts recurrence type. Data regarding the association between …

Risk of first venous thromboembolism (VTE) increases with age. We investigated whether
age is related to the risk of recurrent VTE. We followed 694 patients for a mean of 40 months …

Aim: To determine if the mode of presentation of venous thromboembolism (VTE), as deep
vein thrombosis (DVT) or pulmonary embolism (PE), predicts the likelihood and type of …

Both the clinical aspects of the first VTE event and individual characteristics (such as
associated diseases, inherited or acquired thrombophilic conditions, altered D-dimer results …

Initial treatment for venous thromboembolism (VTE) includes the acute and intermediate
phases, usually lasting for 3 months. The choice to extend therapy beyond the initial 3 …

Currently available anticoagulants are effective in reducing the recurrence rate of venous
thromboembolism (VTE). However, anticoagulant treatment is associated with an increased …